RxDoctor Payments Data

Michael Marshall, MD

Internal Medicine · Cedar Hill, TXNPI 1881668952

Payments from drug & device makers

$69,968in general payments, 2019–2025

Across 129 payments — averaging $542.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acella Pharmaceuticals, LLC$68K
  • Novo Nordisk$324
  • AstraZeneca$234
  • GSK$177
  • Pfizer$164
  • Amgen$162
  • plus $684 from 15 others

What the payments were for

  • Food & beverage$1,72599%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$69,968 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$133,761
Medicare patients
248
Services billed
1,804

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide259$322,097
JardianceEmpagliflozin258$288,559
MounjaroTirzepatide224$279,501
FarxigaDapagliflozin Propanediol118$114,428
TrulicityDulaglutide70$85,140
Repatha SureclickEvolocumab98$72,191
EliquisApixaban55$71,975
JanuviaSitagliptin Phosphate52$57,394
Trelegy ElliptaFluticasone/Umeclidin/Vilanter70$52,743
Praluent PenAlirocumab43$33,108
ProliaDenosumab20$32,571
RybelsusSemaglutide20$28,909
Soliqua 100-33Insulin Glargine/Lixisenatide33$25,824
XareltoRivaroxaban21$18,964
Tresiba Flextouch U-200Insulin Degludec17$18,953

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humulin 70-30$158$367,863307 claims
Novo NordiskOzempic, Rybelsus$324$351,005279 claims
Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr$89$321,414287 claims
AstraZenecaFarxiga$234$114,428118 claims
PfizerEliquis$164$71,97555 claims
MerckJanuvia$26$57,39452 claims
GSKTrelegy Ellipta$177$52,74370 claims
AmgenProlia$162$32,57120 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$48$25,82433 claims
Johnson & JohnsonXarelto$23$18,96421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Cedar Hill

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →